Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study

BACKGROUND: Recombinant human endostatin (rh-endostatin) is a novel antiangiogenesis drug developed in China. Previous experiments have shown that rh-endostatin can inhibit the proliferation and migration of endothelial cells and some types of tumor cells. In this study, we evaluated the efficacy an...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Chen, Jianghao, Yao, Qing, Li, Dong, Zhang, Juliang, Wang, Ting, Yu, Ming, Zhou, Xiaodong, Huan, Yi, Wang, Jing, Wang, Ling
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2013
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3664086/
https://ncbi.nlm.nih.gov/pubmed/23693018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-248
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak